On July 2, Ali Health rose 5.19% in regular trading, trading at HK$3.24/share, with turnover of HK$122 million.

On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (luzunolei sodium tablets, for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taituotuo (toluonadafi tablets, for erectile dysfunction) were simultaneously launched exclusively on Ali Health's platform on June 29. The concurrent selection by two leading domestic pharmaceutical companies of Ali Health as their exclusive online launch channel reinforces the company's positioning as the premier first-launch platform for innovative and specialty drugs, validating its channel value and digital service capabilities in drug commercialization.

Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. The broader Internet and Direct Marketing Retail sector also showed strength, with Meituan-W up 6.42%, JD-SW up 5.19%, JD Health up 4.38%, BABA-W up 3.77%, and PA Good Doctor up 3.72%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)